Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.57 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23735519 | 0.90 | CASP2 (0.55) | FAAHCASP2MEN1KMT2AEPHX2 | |
| SCHEMBL23735430 | 0.90 | CASP2 (0.54) | FAAHCASP2MEN1KMT2AEPHX2 | |
| SCHEMBL23735520 | 0.88 | CASP2 (0.57) | FAAHCASP2MEN1KMT2AEPHX2 | |
| SCHEMBL23735524 | 0.88 | CASP2 (0.57) | FAAHCASP2MEN1KMT2AEPHX2 | |
| SCHEMBL19477898 | 0.88 | FAAH (0.72) | FAAHCASP2MEN1KMT2AEPHX2 | |
| SCHEMBL23735522 | 0.88 | CASP2 (0.56) | FAAHCASP2MEN1KMT2AEPHX2 | |
| SCHEMBL22095994 | 0.86 | FAAH (0.61) | FAAHCASP2KMT2AEPHX2DNM1 | |
| SCHEMBL3318199 | 0.85 | FAAH (0.54) | FAAHCASP2KMT2ATSHR | |
| SCHEMBL22461771 | 0.85 | CASP2 (0.71) | FAAHCASP2EPHX2NAAADNM1 | |
| SCHEMBL22461770 | 0.85 | CASP2 (0.71) | FAAHCASP2EPHX2NAAADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360794-A1 | JAK INHIBITOR | JAK2, JAK1, JAK3 | FAAH 4213/4885CASP2 2390/4885MEN1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.